National Institute on Drug Abuse; Notice of Closed Meetings, 40708 [2016-14777]
Download as PDF
<![CDATA[
40708
Federal Register / Vol. 81, No. 120 / Wednesday, June 22, 2016 / Notices
Neuroscience & Basic Behavioral
Science, National Institute of Mental
Health, National Institutes of Health,
6001 Executive Blvd., MSC9645,
Bethesda, MD 20892–9645,
biospecimens2@mail.nih.gov, 301–443–
3107.
Sample
collection, processing, and storage
procedures have the potential to affect
assay results for basic research,
biomarker discovery, biomarker
validation, and development of
validated assays. Variability in these
procedures may also decrease data rigor,
thereby increasing the likelihood of
irreproducible data, incorrect
conclusions, and delays in advancing
scientific knowledge.
Recent genetic studies have provided
compelling evidence in support of the
long-held hypothesis that alterations in
immune function are associated with
the pathophysiology of mental illnesses.
Abnormal blood levels of cytokines
have been reported in schizophrenia,
bipolar disorder and major depressive
illness. However, our understanding of
the role of immune system markers in
mental illnesses has not advanced due
in part to between-study heterogeneity
in immune assay methodology,
diagnosis criteria, severity of disease,
number and age of samples, and other
potential confounds (e.g., medication,
comorbidities) (Goldsmith, DR et al.,
Mol. Psychiatry, 23 February 2016;
doi:10.1038/mp.2016.3).
The creation of an agreed upon,
standard panel of pro- and antiinflammatory markers, along with
adoption of a standard approach for
sample collection and handling, would
be a valuable resource for evaluation of
inflammatory processes in mental
illnesses.
This request for information (RFI)
seeks information from the community
about the availability, quality, and
degree of clinical characterization of
plasma and CSF samples that could
potentially be used for assessing the
technical performance of a panel of
inflammatory markers and the utility of
the panel for sub-typing individuals and
tracking disease progression in
individuals with mental illness.
The NIMH seeks information on the
following:
1. Source and number of samples
available for each disorder and for
healthy controls. Include the number of
plasma samples and the number of CSF
samples available, and whether both
plasma and CSF samples are available
from the same individuals.
2. SOPs used for sample collection
and storage
mstockstill on DSK3G9T082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
20:02 Jun 21, 2016
Jkt 238001
3. Available clinical data: diagnosis,
age of onset and duration of illness,
demographics, medications, comorbidities
4. Consent for sharing of samples
5. Contact information for the
individual responsible for the samples
Respondents are encouraged to
include any other information that they
deem relevant to the purpose of this
RFI.
The NIH will use the information
submitted in response to this RFI at its
discretion and will not provide
comments to any responder’s
submission. However, responses to the
RFI may be reflected in future funding
opportunity announcements. The
information provided will be analyzed
and may be aggregated in reports.
Respondents are advised that the
Government is under no obligation to
acknowledge receipt of the information
received or provide feedback to
respondents with respect to any
information submitted. No proprietary,
classified, confidential, or sensitive
information should be included in your
response. The Government reserves the
right to use any non-proprietary
technical information in any resultant
solicitation(s).
Dated: June 16, 2016.
Shelli Avenevoli,
Acting Deputy Director, National Institute of
Mental Health.
[FR Doc. 2016–14740 Filed 6–21–16; 8:45 am]
BILLING CODE 4140–01–P
Date: July 14, 2016.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel Summer
Research Education Experience Programs
(R25).
Date: July 19, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Blvd., Room 4245,
Rockville, MD 20852, 301–435–1426,
mcguireso@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 17, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–14777 Filed 6–21–16; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Mechanism for Time-Sensitive Drug Abuse
Research (R21).
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; NLM PEOPLE
LOCATOR® System
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on April 15, 2016,
page 22289 and allowed 60 days for
public comment. There were no
comments received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Library of Medicine (NLM), National
Institutes of Health, may not conduct or
SUMMARY:
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 81, Number 120 (Wednesday, June 22, 2016)]
[Notices]
[Page 40708]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-14777]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Mechanism for Time-Sensitive Drug Abuse Research
(R21).
Date: July 14, 2016.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020,
hiromi.ono@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Summer Research Education Experience Programs (R25).
Date: July 19, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, 301-435-1426,
mcguireso@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: June 17, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-14777 Filed 6-21-16; 8:45 am]
BILLING CODE 4140-01-P
